FIG. 1


1
2
3
4
5
6
7
8
9
10
11
12
13
CH3CN
Hg(AcO)2
HCl
EtOAc
Ac2O
Pyridine
DMF
POCl3
Benzene
Ph3P
Di-t-butyldicarbonate
LiOH

FIG. 2


Z-CINN
HX1A
PDT
JR3
R2
O
OH
R4
R1
Z
R6
R5
+ Drug-OH
DMAP
O-Drug
+ Drug-NH2
EDC/DMF
NH-Drug
+ Protein-NH2
EDC/DMF
NH-Protein
NH2
+ Drug-OH
EDC/DMF
NH-Drug
NHNH2
+ Drug-COOH
EDC
NH-NH-C=O-Drug

FIG.3



FIG. 4



FIG. 5



FIG. 6



FIG. 7


A-Z-CINN 310
A-Z-CINN 310.5
A-Z-CINN 310.1
Control 1
251
108
88
82
300
250
200
150
100
50
0
7
14
21
28
TUMOR VOLUME (mm3)
DAYS POST-TREATMENT

FIG. 8


Systemic - Control 2
Targeted - A-Z-CINN 310
TUMOR VOLUME (mm3)
300
250
200
150
100
50
0
7
14
21
28
DAYS POST-TREATMENT
208
256
256
226
161
100
88
88
88
88

FIG. 9


Passive - A-Z-CINN 310.1
Active - A-Z-CINN 310.1
TUMOR VOLUME (mm3)
300
250
200
150
100
50
208
220
196
172
126
196
126
108
108
108
0
7
14
21
28
DAYS POST-TREATMENT


Systemic Control 2
Passive - A-Z-CINN 310.1
300
250
200
150
100
50
TUMOR VOLUME (mm3)
0
7
14
21
28
DAYS POST-TREATMENT
256
256
208
226
220
161
196
172
126

FIG. 10